Skip to content
Search

Latest Stories

BREAKING: MHRA recalls Picato 150 mcg/g and 500 mcg/g gel

The Medicines and Health products Regulatory Agency (MHRA) today issued a class 2 medicines recall for Picato 150 mcg/g and 500 mcg/g gel.

LEO Pharma is recalling all unexpired stock of the products from pharmacies and wholesalers as a precautionary measure due to concerns on the possible risk of skin malignancy.


This is following the suspension of the marketing authorisation of Picato (ingenol mebutate), while the investigations are ongoing.

“Stop prescribing Picato and consider other treatment options as appropriate. For patients who have recently been prescribed Picato, advise patients to be vigilant for any skin lesions developing and to seek medical advice promptly should any occur,” the government agency advised healthcare professionals.

Pharmacists are asked to stop supplying the products immediately, quarantine remaining stock and return it to the supplier using the approved process.

Healthcare professionals are also asked to report any suspected adverse reactions via Yellow Card Scheme www.mhra.gov.uk/yellowcard or MHRA Yellow Card app.

Product details:

ProductMarketing Authorisation Number
Picato 150 mcg/g gel ▼EU/1/12/796/001
Picato 500 mcg/g gel ▼EU/1/12/796/002
Batch NumberExpiry DatePack SizeFirst Distributed
A69570AJan-203 x 0.47g tubes18-Apr-18
A69570BJan-203 x 0.47g tubes06-Jun-18
A72947AFeb-203 x 0.47g tubes06-Jun-18
A75024AApr-203 x 0.47g tubes18-Jul-18
A78808AMay-203 x 0.47g tubes05-Sep-18
A80602BJun-203 x 0.47g tubes12-Sep-18
A80602AJun-203 x 0.47g tubes12-Sep-18
A89440ANov-203 x 0.47g tubes22-Jan-19
A92248ADec-203 x 0.47g tubes11-Feb-19
A98938AMar-213 x 0.47g tubes16-May-19
C01098AApr-213 x 0.47g tubes24-Jun-19
C10894AAug-213 x 0.47g tubes22-Oct-19
C14179AOct-213 x 0.47g tubes06-Dec-19
A76669AApr-202 x 0.47g tubes22-Aug-18
A88113AOct-202 x 0.47g tubes11-Dec-18
A98419AMar-212 x 0.47g tubes16-May-19
C03413AMay-212 x 0.47g tubes29-Aug-19
C11902ASep-212 x 0.47g tubes08-Nov-19

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less